Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDV9300 in Relapsed/Refractory DLBCL
NCT02653989Phase 2Withdrawn
- Sponsor
- Medivation
- Start
- Dec 2016
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pidilizumab in diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), transformed indolent lymphoma (TIL), sponsored by Medivation. Planned start Dec 2016; status: withdrawn.
02
Drugs
pidilizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)transformed indolent lymphoma (TIL)
Beyond the preview
Go deeper on NCT02653989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02653989.